Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Massachusetts

Phase 3 cancer trials in Massachusetts

94 Phase 3 cancer studies are recruiting participants at sites in 22 cities across Massachusetts as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Massachusetts city with a recruiting study

By research area: Lung Cancer (34), Breast Cancer (25), Lymphoma (15), Prostate Cancer (9), Melanoma (6), Pancreatic Cancer (5).

Boston (79), Worcester (16), Burlington (14), Beverly (9), Peabody (9), Gloucester (8), Methuen (8), Foxborough (7), South Weymouth (7), Springfield (7), Milford (6), Brighton (4), Lowell (4), Stoneham (4), Newburyport (3), Winchester (3), Weymouth (2), Fairhaven (1), Fall River (1), Jamaica Plain (1), Newton (1), Plymouth (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Massachusetts

Basic details from each study's public record (the 12 most recently updated of 94). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Boston
    Registry record
    NCT06966700 · updated
  2. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Recruiting in
    Boston
    Registry record
    NCT05696626 · updated
  3. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Boston
    Registry record
    NCT05894239 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Massachusetts on ClinicalTrials.gov.

Lung cancer: recently updated in Massachusetts

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Beverly · Burlington · Gloucester · and 3 more U.S. locations
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Boston · Brighton · Foxborough · and 4 more U.S. locations
    Registry record
    NCT06767514 · updated
  3. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Recruiting in
    Boston
    Registry record
    NCT06899126 · updated
  4. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Boston
    Registry record
    NCT07195695 · updated
  5. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Boston
    Registry record
    NCT06623422 · updated
  6. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Mirati Therapeutics Inc.
    Recruiting in
    Boston
    Registry record
    NCT06875310 · updated
  7. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Amgen
    Recruiting in
    Worcester
    Registry record
    NCT05920356 · updated
  8. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Boston
    Registry record
    NCT07063745 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Massachusetts on ClinicalTrials.gov.

Lymphoma: recently updated in Massachusetts

  1. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Recruiting in
    Boston
    Registry record
    NCT05303519 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Massachusetts on ClinicalTrials.gov.

Ask about studies in Massachusetts

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call